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Probiotics are living microorganisms that provide a wide variety of health benefits to the host when ingested in
adequate amounts. The bacterial strains most frequently used as probiotic agents are lactic acid bacteria, such as
Lactobacillus reuteri, which is one of the few endogenous Lactobacillus species found in the gastrointestinal tract
of vertebrates, including humans, rats, pigs and chickens. L. reuteri is one of the most well documented probiotic
species and has been widely utilized as a probiotic in humans and animals for many years. Initially, L. reuteri was
used in humans to reduce the incidence and the severity of diarrhea, prevent colic and necrotic enterocolitis, and
maintain a functional mucosal barrier. As interest in alternatives to in-feed antibiotics has grown in recent years,
some evidence has emerged that probiotics may promote growth, improve the efficiency of feed utilization, prevent
diarrhea, and regulate the immune system in pigs. In this review, the characteristics of L. reuteri are described, in order
to update the evidence on the efficacy of using L. reuteri in pigs.
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Antibiotics are a common additive in livestock feed
which have been widely used for growth promotion and
prophylaxis purposes in farm animals during the past
several decades [1]. However, antibiotic resistance is a
looming public health crisis. The use of antibiotics as
growth promoters has been forbidden in the European
Union, Korea, and Japan. Other countries including the
United States and China may ban the feeding of antibi-
otics within the next few years. As a result, there is in-
creasing interest concerning alternatives to in-feed
antibiotics, such as probiotics, prebiotics, plant products
and organic acids in the livestock industry [2].
Probiotics are living microorganisms, which, when
consumed in adequate amounts, can confer a health
benefit to the host [3]. In farm animals, probiotics have
been shown to promote growth, improve the efficiency
of feed utilization, modulate the gastrointestinal ecosys-
tem, stimulate the immune system and protect the host
from gastrointestinal tract (GIT) diseases [4]. Therefore,
probiotics provide a potential alternative strategy to in-
feed antibiotics [5].* Correspondence: qiaoshy@mafic.ac.cn
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unless otherwise stated.The properties of probiotics are strain-specific, and
suitable probiotic strains for pigs are usually selected
based on some criteria including pig origin, acid and
bile tolerance, their ability to adhere to intestinal cells
and to colonise the intestinal tract, production of anti-
microbial substances, antibiotic resistance patterns,
demonstrable efficacy and safety, and stability to the
conditions used in industrial processes [6-8]. The or-
ganisms most frequently used as probiotic agents are
lactic acid bacteria (LAB) [9], such as Lactobacillus,
which are a normal inhabitant of the GIT [10]. Lacto-
bacillus reuteri is one of the dominant species in the
GIT of vertebrates such as humans, rats, pigs and
chickens [11]. It is one of the most well documented
probiotic species and has been widely utilized as a pro-
biotic in humans and animals [12-15].
In recent years, numerous probiotic strains have
been used in pig production. The application of pro-
biotics provide a potential alternative strategy to the
use of antibiotics. The aim of this review is to system-
atically review and update the evidence on the efficacy
of using L. reuteri in pigs.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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L. reuteri is a heterofermentative bacterium, and is consid-
ered to be one of the few true autochthonous Lactobacillus
species in humans and animals. Many researchers have
already selected some specific L. reuteri strains isolated
from human feces, breast milk, the human vagina, the
human oral cavity, guinea pigs, rats, pigs, broilers and
sourdough. There is now mounting evidence to show
that selected L. reuteri strains have probiotic character-
istics, and can provide health benefits to their hosts. We
have constructed a summary table (Table 1), in order to
provide an overview of the reported L. reuteri strains
used as probiotics.Table 1 The strains and probiotic characteristics of reported L
Strain Source Characteristics
L. reuteri I5007 piglets strong adhesion, competitiveness
immune function and antioxidant
modulated gut microflora
L. reuteri NCIMB 30242 pig improve gastrointestinal health; in
circulating 25-hydroxyvitamin D
L. reuteri ATCC 53608 pig recognize immunoglobulins
L. reuteri BSA131 pig resistance to pH, oxgall and antib
pathogenic, improved pig perform
L. reuteri Pg4 broilers tolerate acid and bile salts; inhibit
epithelial cells; improved broiler p
L. reuteri ATCC 55730 breast milk colonize the intestinal tract; resist
intestinal health; prevent diarrhea
treatment of Helicobacter pylori
L. reuteri DSM 17938 ATCC 55730 a daughter strain derived from AT
as ATCC 55730
L. reuteri ATCC PTA 4659 breast milk partly prevent diet-induced obesi
liver expression of Cpt1a.
L. reuteri ATCC PTA 6475 breast milk protect mice from disease manife
L. reuteri ATCC PTA 5289 oral cavity improve oral malodour; reduce th
in the subgingival microbiota
L. reuteri DPC16 human feces produce reuterin
L. reuteri DSM 20016 human feces produce reuterin
L. reuteri JCM 1112 human feces produce reuterin and cobalamin
L. reuteri RC-14 human vagina produce hydrogen peroxide; adhe
uropathogens; modulate immunit
L. reuteri GMN-32 - regulate blood glucose levels, pro
cardiomyopathy in diabetes melli
L. reuteri DSMZ 17648 - reduce the load of Helicobacter py
L. reuteri GMNL-263 - ameliorate hepatic steatosis obse
streptozotocin-induced diabetic r
L. reuteri R2 - strong inhibitory activity against t
L. reuteri TD1 rat not produce reuterin, exhibit a sim
L. reuteri 100-23 rat stimulate the development of regul
L. reuteri BR11 guinea pig unique antioxidant properties, sho
L. reuteri CRL1098 sourdough produce vitamin B12
L. reuteri LTH2584 sourdough produce reutericyclin
Note: L. reuteri I5007, initially known as L. fermentum I5007; L. reuteri BR1, initially knowProbiotic properties
Probiotic bacteria encounter various stresses after inges-
tion by the host, including exposure to a low pH in the
stomach and contact with bile in the small intestine.
L. reuteri I5007, initially known as Lactobacillus fermen-
tum I5007, was selected from over 7,000 native Lactoba-
cilli colonies according to criteria including resistance to
heat, low pH, copper, and bile salts, as well as storage sta-
bility and antagonism to pathogenic agents [16]. Other
L. reuteri strains also show resistance to low pH and bile
salts [12,17-19].
Adhesion of a probiotic strain to the host GIT is im-
portant for bacterial colonization, pathogen exclusion,. reuteri
Reference
against pathogens; improved pig performance,
status; alleviated the weaning stress syndrome;
[21,35,46-48,50,52]
hibite sterol absorption; increase mean [61-63]
[24,41]
iotics, and antimicrobial activities against enteric
ance
[12]
pathogenic bacteria; adhere to intestinal
erformance
[17]
ance to tetracycline and lincomycin; maintain
; modulate the immune system; used in
[13,14,64,65]
CC 55730 and has the same properties [42]
ty possibly via the mechanism of inducing [66]
stations of enterohemorrhagic E. coli [67]




re to uroepithelial cells and inhibit
y
[28,70]




rved in high fructose treated rats; protect
ats from hyperglycemia-enhanced renal fibrosis
[73,74]
he dermatophyte Trichophyton tonsurans [75]
ilar onset of type 1 diabetes [76]
atory T cells; transiently activates intestinal epithelial cells [36,77]
w promise in the treatment of experimental colitis [37]
[34]
[32]
n as L. fermentum BR11; L. reuteri RC-14, initially known as L. fermentum RC-14.
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thelial cells or immune modulation [20]. Several studies
have demonstrated that L. reuteri have the capacity to
colonize, and can adhere to mucin and intestinal epithelial
cells [17,21-23]. L. reuteri I5007 shows strong adhesion to
Caco-2 cells, IEC-6 cells, IPEC-J2 cells, and porcine intes-
tinal mucus [15,21]. The possible mechanism for L. reuteri
adherence and colonization involved in adhesion, has been
linked to mucus-binding protein [24], surface protein [22],
D-alanyl-LTA [25], exopolysaccharide [26], glucosyltrans-
ferase A and inulosucrase [27].
L. reuteri has been reported to produce a variety of anti-
microbial substances such as lactic acid, hydrogen perox-
ide [28], reuterin [29-31], and reutericyclin [32], which
have beneficial effects for the host organism. L. reuteri
strains have been demonstrated to inhibit the in vitro
growth of many enteric pathogens, including Escherichia
coli, Salmonella Typhimurium, Staphylococcus epidermi-
dis, Staphylococcus aureus, Helicobacter pylori, and rota-
virus [12,19,33]. In addition, L. reuteri can produce
vitamin B12 [31,34], and has the capacity to de novo
synthesize L-lysine and folic acid based on a computer
simulation model [15].
L. reuteri exhibited free radical-scavenging capacity
in vitro [35], and encoded various antioxidant enzymes
[15]. Studies in animals and humans have shown that
oral administration of L. reuteri reduced the incidence
and the severity of diarrhea, decreased visceral pain, pre-
vented colic and necrotic enterocolitis, maintained a
functional mucosal barrier, and induced colonization
and immunomodulation [36-39].
Safety and stability aspects
L. reuteri has the most extensive safety assessment rec-
ord of any probiotic strain. A number of studies con-
ducted both in vivo and in vitro indicate that L. reutei is
safe for human consumption, even in large amounts
[38,40]. However, as is the case for all other species of
LAB, plasmids can be found in some strains of L. reuteri
[15,41,42], and some of these plasmids have been shown
to encode for antibiotic resistance genes [42]. According
to the European Food Safety Authority, probiotics should
not contain known antibiotic resistance traits. L. reuteri
ATCC 55730 is a commercially available probiotic strain
which has been found to carry potentially transferable re-
sistance traits for tetracycline and lincomycin. Therefore,
it has been replaced by L. reuteri DSM 17938, a strain
where the two resistance plasmids have been removed
without losing any probiotic characteristics [42].
Probiotic strains must be able to resist any adverse
conditions encountered during industrial production in
order to survive [43]. L. reuteri is sensitive to heat, and
therefore, freeze-drying is commonly used for maintain-
ing the stability of L. reuteri. Subjecting L. reuteri to ahigher fermentation temperature (47°C) or a neutral pH
(pH 6.7) has been shown to increase the survival of
L. reuteri during subsequent freeze-drying [44].
Strains
Not all L. reuteri strains are the same or provide a bene-
ficial response, and the evolution of L. reuteri with verte-
brates resulted in the emergence of host specialization
[45]. Probiotic strains need to be carefully chosen, and
evaluated for their safety and effectiveness using in vitro
assays, animal models, and clinical trials. There are nu-
merous strains of L. reuteri, which have some minor dif-
ferences that make them unique (Table 1).
L. reuteri DSM 17938, L. reuteri NCIMB 30242, L.
reuteri ATCC PTA 6475 which are of human origin are
the most commonly used in dietary supplements and
have been researched the most. In pigs, L. reuteri I5007,
was isolated from the colonic mucosa of healthy wean-
ing piglets, and has been demonstrated in several stud-
ies to have probiotic properties [15,21,35,46-49].
Applications of probiotic L. reuteri for pigs
In pigs, the administration of L. reuteri has been shown
to have beneficial effects on performance, prevention of
diarrhea, stress relief, altered gut microbiota, and immu-
nomodulation. The applications of L. reuteri for pigs are
listed in Table 2. Noticeably, L. reuteri is mainly used in
neonatal piglets and during the post-weaning period.
Improved performance
In the pig industry, the use of probiotics improves intes-
tinal health which can improve pig performance. Supple-
mentation of L. reuteri has resulted in improved growth
and feed efficiency in neonatal and growing pigs. Liu
et al. [46] reported that L. reuteri I5007 (6 × 109 CFU/d)
supplementation increased average daily gain (ADG) in
formula-fed piglets. Wang et al. [47] found that adminis-
tration of L. reuteri I5007 significantly increased weight
gain and feed conversion compared with weaned pigs fed
without L. reuteri I5007. Also, Wang et al. [50] reported
that weaned piglets supplemented with L. reuteri had faster
growth and higher feed intakes than unsupplemented pig-
lets. However, feed conversion was unaffected by L. reuteri
supplementation. In addition, Wang et al. [48] showed that
dietary supplementation with L. reuteri or aureomycin sig-
nificantly improved the performance of weanling piglets,
and there was no difference between the two feed additives.
Other studies using L. reuteri BSA131 tended to show im-
proved ADG and feed conversion in weaned pigs [12].
Wang et al. [51] also reported that supplementation with
L. reuteri X-1 increased ADG and feed conversion. Yu
et al. [52] determined the influence of different levels of
L. reuteri I5007 on performance, nutrient digestibility
and immunity of weaned pigs. The results demonstrated
Table 2 The application of probiotic L. reuteri in pigs
Strain Dose Animal Significant results Reference
L. reuteri I5007 6 × 109 CFU/d newborn piglets increased average daily gain; reduced diarrhea incidence; affected
the colonic microbial communities , in particular, reduced numbers
of Clostridium sp; reduced mRNA expression of IL-1β in the ileum
[46]
L. reuteri I5007 2× 109 CFU/d weaned pigs increased weight gain and feed conversion; decreased the
occurrence of diarrhea; enhanced T-cell differentiation
and induced cytokine expression in the ileum
[47]
L. reuteri I5007 2× 109 CFU/d weaned pigs had faster growth and higher feed intakes; improved the
anti-oxidative defence system and alleviated damage
caused by diquat
[50]
L. reuteri I5007 5.8 × 107 CFU/g weaned pigs increased weight gain, feed intake and apparent crude protein
digestibility; increased serum specific anti-OVA IgG level
[52]
Lactobacilli complex 105 CFU/g weaned pigs increased weight gain and feed intake compared with carbadox;
prevented diarrhea; decreased E. coli and aerobe counts, increased
Lactobacilli and anaerobe counts in digesta and mucosa
[16]
L. reuteri BSA131 2× 106, 2× 108 CFU/g weaned pigs improved weight gain and feed conversion; decreased
the number of enterobacteria in the feces
[12]
L. reuteri X-1 108 CFU/g weaned pigs improved weight gain and feed conversion; decreased
serum IgG and IgM concentrations, incresed serum
DAO and D-lactate concentrations
[51]
L. reuteri I5007 1.02 × 108 CFU/g growing pigs increased total antioxidant capacity [35]
L. reuteri I5007 108 CFU/g weaned pigs increaed weight gain, neither body weights nor weight
gains differed between the L. reuteri and aureomycin groups;




106 CFU/g weaned pigs increased apparent total tract digestibility of nitrogen,
gross energy, and fecal Lactobacillus concentration;
decreased fecal gas emission, diarrhea score, and
E. coli concentration
[78]
L. reuteri 3S7 and
L. plantarum 4.1
1010 CFU/d sows and piglets were found in the faeces; decreased the population of
Enterobacteriaceae; decreased β-glucuronidase activity of all pigs
[79]
Note: L. reuteri I5007 was initially known as L. fermentum I5007.
Lactobacilli complex including L. gasseri, L. reuteri, L. acidophilus and L. fermentum (renamed L. reuteri I5007).
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was 5.8 × 107 CFU/g feed.
Prevention of diarrhea
Diarrhea is one of the most frequent causes of heavy eco-
nomic losses in swine operations [53]. The effect of L. reu-
teri against diarrhea in pigs was confirmed in several
reports [16,46,47,54,55]. Diarrhea incidence was lower in
piglets fed L. reuteri I5007 compared with a control [46].
Enterotoxigenic E. coli (ETEC) are a major cause of diar-
rhea in neonatal and weaned pigs [55]. Huang et al. [16]
showed that a native Lactobacilli complex preparation (in-
cluding L. gasseri, L. reuteri, L. acidophilus and L. fermen-
tum) could effectively prevent weaning piglet diarrhea
when administered before challenge with an E. coli solution
(serovars K99, K88 and 987P at a ratio of 1:1:1). Wang et
al. [47] reported that 12, 24, and 48 h after challenge, pigs
challenged with E. coli had mild diarrhea and mild fecal
scores. Supplementation of L. reuteri I5007 did not alleviate
these effects. Only on day 10, did feeding L. reuteri I5007
decrease the occurrence of diarrhea. Chen et al. [54] dem-
onstrated that reuteran produced by L. reuteri may prevent
piglet diarrhea by reducing adhesion of ETEC K88.Alleviate stress
Pigs in industrial farming systems are frequently exposed
to oxidative stress, which results in decreased perform-
ance and reduced immune function. L. reuteri has been
shown to be effective in scavenging free radicals
in vitro, and could be used to alleviate oxidative stress
[35,37]. Wang et al. [35] reported that supplementation
of L. reuteri I5007 improved the antioxidant status of
growing-finishing pigs (from 50 to 90 kg) as evidenced
by increased levels of antioxidant enzymes such as
superoxide dismutase and glutathione peroxidase, and
decreased levels of malondialdehyde. Wang et al. [50]
determined the anti-oxidative effect of L. reuteri I5007
in weaning piglets using an oxidative stress model in-
duced by diquat. Their results showed that diquat-
injection decreased the performance of weaning pigs
and increased plasma levels of cortisol, adrenaline, car-
bonyl and malondialdehyde. L. reuteri supplementation
alleviated oxidative stress and enhanced the perform-
ance of weanling pigs.
Weaning is one of the most stressful periods that results
in gastrointestinal, immunological, and behavioral changes
[56]. Wang et al. [48] demonstrated that L. reuteri I5007
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levels of proteins involved in energy metabolism, lipid me-
tabolism, cell structure and mobility, protein synthesis,
and immune response, thereby facilitating cellular prolifer-
ation and depressing apoptosis.
Modulation of gut microbiota
L. reuteri in neonatal piglets can be used to support the
development of a stable microbiota, to stimulate the im-
mune system and to prevent diarrheal diseases. During
the weaning and post-weaning periods, L. reuteri is used
in pigs to modulate the gastrointestinal microbiota as it
aims to prevent post-weaning diarrhea and stimulate
growth. Liu et al. [46] reported that L. reuteri I5007
plays a positive role in gut development in neonatal piglets
by modulating the microbial composition and intestinal
development, Denaturing gradient gel electrophoresis
(DGGE) revealed that L. reuteri I5007 affected the colonic
microbial communities on day 14 and, in particular, re-
duced numbers of Clostridium spp. In weaning pigs, ad-
ministration of L. reuteri BSA131 decreased the number
of enterobacteria in the feces [12]. Huang et al. [16]
showed that a Lactobacilli compound (including L. gasseri,
L. reuteri, L. acidophilus and L. fermentum) significantly
decreased E. coli and aerobe counts, and increased Lacto-
bacilli and anaerobe counts in the digesta and mucosa of
most sections of the GIT compared with a control group.Figure 1 Mechanisms of L. reuteri modulating in the gut. ① L. reuteri c
acid, and reuterin [28-30]. ② L. reuteri has the capacity to colonize, and can
has been shown to stimulate or suppress innate immune responses by affe
dendritic cells (DCs). The modulation of dendritic cells by L. reuteri has bee
adhesion molecule-3-grabbing non-integrin (DC-SIGN) and promote develo
(IL-10) and transforming growth factor-β (TGF-β) [59,60]. ④ L. reuteri has be
chain fatty acid (SCFA) concentration [46]. Please see text for details and reIn addition, oral administration of L. reuteri I5007 not
only increased the concentration of butyrate and other
branched chain fatty acids but also decreased Clostridium
strains accompanied by a lowered pH in the colonic
digesta [46]. This indicates that administration of L. reuteri
modulates gut microbiota, and thereby affected the micro-
bial metabolites.
Immunomodulation
Probiotics such as L. reuteri may stimulate or suppress in-
nate immune responses via several mechanisms including
modulation of pro-inflammatory cytokines. L. reuteri
strains can be divided into two subsets, immunosuppres-
sive (ATCC PTA 6475 and ATCC PTA 5289) and immu-
nostimulatory strains (ATCC 55730 and CF48-3A), and
each subset has potential therapeutic value [57]. The ef-
fects of L. reuteri on immunomodulation were docu-
mented in pigs. Wang et al. [47] reported that oral
administration of L. reuteri I5007 could enhance T-cell dif-
ferentiation and induce ileal cytokine expression, which
suggests that this probiotic strain could modulate immune
function in weaned piglets. Yu et al. [52] showed that
L. reuteri I5007 supplementation increased serum specific
anti-OVA IgG levels. In neonatal piglets, L. reuteri has
been found to decrease the mRNA expression of IL-1β in
the ileum [46]. Azevedo et al. [58] found that L. reuteri
combined with L. acidophilus could help to maintainan produce a variety of antimicrobial substances (AMS) such as lactic
adhere to mucin and intestinal epithelial cells [17,21,22] . ③ L. reuteri
cted the production of cytokines in macrophages (M), monocytes, and
n shown to be mediated through dendritic cell-specific intercellular
pment of regulatory T cells producing high amounts of interleukin-10
en reported affected the colonic microbial communities and short
ferences.
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infected with human rotavirus by regulating TGF-β
production.
Conclusions and perspectives
In conclusion, L. reuteri is a probiotic bacteria that is
one of the few true autochthonous Lactobacillus species.
Numerous studies have demonstrated that they can posi-
tively improve performance, prevent diarrhea, alleviate
stress, alter gastrointestinal microbiota, regulate the im-
mune system, and thereby improve pig performance and
health. The beneficial effects of L. reuteri in pigs have been
related to different modes of action. The improvements in
pig performance of supplemental L. reuteri are mostly due
to the fact that L. reuteri has the ability to colonize the
GIT, produce antimicrobial substances and stimulate the
intestinal immune system (Figure 1), thereby promoting
nutrient metabolism and improve health. However, a clear
mode of action has yet to be described. It appears from
the data presented that the benefical effects of L. reuteri
are strain specific. It will be important to select more
powerful or targeted strains. Unfortunately, the viability of
L. reuteri is a key criteria for developing L. reuteri prod-
ucts. To expand the probiotic L. reuteri application in pigs,
care must be taken during processing techniques such as
microencapsulation to maintain bacterial stability.
Pig husbandry has entered an era when the use of an-
tibiotics is increasingly unwelcomed. Probiotics, which
are a potential alternative to in feed antibiotics, can ex-
pect a promising future. Besides selection of excellent
strains and improved processing techniques, more re-
search, especially in the form of well-designed animal
trials, is needed to evaluate the efficacy of L. reuteri.
More studies are also needed to explore the mechanisms
of action of L. reuteri in pigs. An important fact is that
L. reuteri added to pig diets may potentially help im-
prove performance. With evolving knowledge, effective
use of L. reuteri will be possible in the future.
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